NeoTX Therapeutics Ltd.
🇮🇱Israel
- Country
- 🇮🇱Israel
- Ownership
- Private
- Established
- 2015-01-01
- Employees
- 11
- Market Cap
- -
- Website
- http://www.neotx.com
NAP in Combination With Docetaxel Following Obinutuzumab Pretreatment in Subjects With Checkpoint Inhibitor Pretreated Advanced or Metastatic NSCLC
Phase 2
Completed
- Conditions
- Non-small Cell Lung Cancer
- Interventions
- First Posted Date
- 2021-05-11
- Last Posted Date
- 2025-03-03
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 38
- Registration Number
- NCT04880863
- Locations
- 🇺🇸
NeoTX - 10312, El Paso, Texas, United States
🇺🇸NeoTX - 10310, Tyler, Texas, United States
🇺🇸NeoTX - 10308, Austin, Texas, United States
Naptumomab Estafenatox in Combination with Durvalumab in Subjects with Selected Advanced or Metastatic Solid Tumor, Including a Cohort Expansion in Esophageal Cancer.
Phase 1
Recruiting
- Conditions
- ER+ Breast CancerOvarian CancerCervical Squamous Cell CarcinomaPancreatic AdenocarcinomaEndometrial CancerRenal Cell CarcinomaUrothelial CancerHead and Neck Squamous Cell CarcinomaMesotheliomaMelanoma
- Interventions
- Combination Product: Obinutuzumab pretreatment (Gazyva®) Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)Combination Product: Naptumomab estafenatox (ABR-217620; NAP) and durvalumab (IMFINZI; MEDI4736)
- First Posted Date
- 2019-06-12
- Last Posted Date
- 2025-03-18
- Lead Sponsor
- NeoTX Therapeutics Ltd.
- Target Recruit Count
- 120
- Registration Number
- NCT03983954
- Locations
- 🇮🇳
Shalby Hospital, Ahmedabad, Gujarat, India
🇮🇳National Cancer Institute, Jhajjar, Haryana, India
🇮🇳PMCH (Pacific Medical College & Hospital), Udaipur, Rajasthan, India
© Copyright 2025. All Rights Reserved by MedPath